Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel is supported with funding from Prothena (Silver).

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMW 2019 | AL amyloidosis treatment options

Vaishali Sanchorawala • 14 Sep 2019
IMW 2019
Amyloidosis Multiple Myeloma Rare Diseases Bortezomib Dexamethasone Melphalan

Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses different options for AL amyloidosis treatments, depending on eligibility for STEM cell transplant, and the subsequent success of these treatments. Interview recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Vaishali Sanchorawala

Updated results with the bispecific antibody etentamig in patients with R/R AL amyloidosis
2:17
Updated results with the bispecific antibody etentamig in patients with R/R AL amyloidosis
Vaishali Sanchorawala • 8 Dec 2025
Cardiac safety of two Dara-VCd dosing schedules in newly diagnosed AL amyloidosis: AQUARIUS trial
5:43
Cardiac safety of two Dara-VCd dosing schedules in newly diagnosed AL amyloidosis: AQUARIUS trial
Vaishali Sanchorawala • 8 Dec 2025
Key agents of interest in the AL amyloidosis space with trial updates presented at ASH 2025
1:03
Key agents of interest in the AL amyloidosis space with trial updates presented at ASH 2025
Vaishali Sanchorawala • 8 Dec 2025
Amyloidosis Sessions: Highlights from ASH 2024
Amyloidosis Sessions: Highlights from ASH 2024
Vaishali Sanchorawala • 8 Dec 2024

Related Videos

Favorable tolerability and early outcomes with full dose lenalidomide in older adults with NDMM
1:37
Favorable tolerability and early outcomes with full dose lenalidomide in older adults with NDMM
Vaishali Sanchorawala • 8 Dec 2025
The global ABNL-MARRO trials and revised response criteria for MDS/MPN overlap syndromes
1:24
The global ABNL-MARRO trials and revised response criteria for MDS/MPN overlap syndromes
Vaishali Sanchorawala • 6 Dec 2025
A novel remote monitoring system to support outpatient administration of bispecific T-cell engagers
2:35
A novel remote monitoring system to support outpatient administration of bispecific T-cell engagers
Vaishali Sanchorawala • 15 Dec 2025
Impact of race and social deprivation on clinical outcomes in newly diagnosed multiple myeloma
2:53
Impact of race and social deprivation on clinical outcomes in newly diagnosed multiple myeloma
Vaishali Sanchorawala • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals